These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 2185341

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer.
    Coombes RC, Hughes SW, Dowsett M.
    Eur J Cancer; 1992; 28A(12):1941-5. PubMed ID: 1419285
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. 4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer.
    Coombes RC.
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):145-8. PubMed ID: 1525056
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
    Goss PE, Powles TJ, Dowsett M, Hutchison G, Brodie AM, Gazet JC, Coombes RC.
    Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE, Clark RM, Ambus U, Weizel HA, Wadden NA, Crump M, Walde D, Tye LM, De Coster R, Bruynseels J.
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer.
    Noberasco C, Bajetta E, Zilembo N, Di Leo A, Cappuzzo F, Bartoli C, Bono A, Bichisao E.
    Oncology; 1995 Mar; 52(6):454-7. PubMed ID: 7478430
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
    Reed MJ, Lai LC, Owen AM, Singh A, Coldham NG, Purohit A, Ghilchik MW, Shaikh NA, James VH.
    Cancer Res; 1990 Jan 01; 50(1):193-6. PubMed ID: 2293555
    [Abstract] [Full Text] [Related]

  • 16. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.
    Coombes RC, Goss P, Dowsett M, Gazet JC, Brodie A.
    Lancet; 1984 Dec 01; 2(8414):1237-9. PubMed ID: 6150277
    [Abstract] [Full Text] [Related]

  • 17. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
    MacNeill FA, Jacobs S, Dowsett M, Lonning PE, Powles TJ.
    Cancer Chemother Pharmacol; 1995 Dec 01; 36(3):249-54. PubMed ID: 7781147
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.